NHS approves new treatment for aggressive cancer that could triple life expectancy

Also known as Ziihera, the antibody treatment targets a protein called HER2, which stimulates tumour growth. It works by activating the immune system to eliminate cancer cells and reduces HER2 levels

Go to News Site